文献速递疼痛医学

炎症小体作为疼痛治疗靶点

The inflammasome as a target for pain therapy.
PubMed 文献 · Br J Anaesth · 2016-01-01

本文为叙述性综述,概述炎症小体的激活与调控机制,探讨抑制炎症小体在复杂区域疼痛综合征、痛风、类风湿关节炎、炎性疼痛、神经病理性疼痛、慢性前列腺炎、慢性盆腔疼痛综合征及纤维肌痛等疼痛相关疾病中的潜在治疗作用。结论认为炎症小体在疼痛相关疾病中的作用可能具有炎症小体亚型特异性和疾病特异性,疾病特异性靶向炎症小体复合物的组装和活性可能为难治性疼痛提供新的治疗机会。

要点

  • 炎症小体激活caspase-1并启动促炎级联,是疼痛相关疾病的潜在治疗靶点。
  • 炎症小体在疼痛疾病中的作用可能因亚型和疾病类型而异。
  • 疾病特异性靶向炎症小体组装与活性可能为难治性疼痛提供新策略。

核心结论

  • 炎症小体在疼痛相关疾病中的作用可能具有炎症小体亚型特异性和疾病特异性。
  • 现有证据提示疾病特异性靶向炎症小体复合物的组装和活性可能为难治性疼痛提供新的治疗机会。

研究设计与样本

  • 叙述性综述,未报告检索范围与样本量。

主要发现

  • 白细胞介素-1家族细胞因子是炎症和疼痛的强效诱导因子,其蛋白水解激活受多种先天免疫受体协调形成的大型多蛋白信号平台即炎症小体调控。
  • 近期证据提示多种以疼痛为常见主诉的炎症性疾病、癌症、代谢性和自身免疫性疾病可能由炎症小体协调。
  • 炎症小体激活导致caspase-1裂解,随后启动下游多个强效促炎级联。

临床怎么用

  • 疾病特异性靶向炎症小体复合物的组装和活性可能作为难治性疼痛的新型治疗策略。

局限性

  • 本文为叙述性综述,未报告系统检索策略、纳入标准及定量合成方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The interleukin-1 family of cytokines are potent inducers of inflammation and pain. Proteolytic activation of this family of cytokines is under the control of several innate immune receptors that coordinate to form large multiprotein signalling platforms, termed inflammasomes. Recent evidence suggests that a wide range of inflammatory diseases, cancers, and metabolic and autoimmune disorders, in which pain is a common complaint, may be coordinated by inflammasomes. Activation of inflammasomes results in cleavage of caspase-1, which subsequently induces downstream initiation of several potent pro-inflammatory cascades. Therefore, it has been proposed that targeting inflammasome activity may be a novel and effective therapeutic strategy for these pain-related diseases. The purpose of this narrative review article is to provide the reader with an overview of the activation and regulation of inflammasomes and to investigate the potential therapeutic role of inflammasome inhibition in the treatment of diseases characterized by pain, including the following: complex regional pain syndrome, gout, rheumatoid arthritis, inflammatory pain, neuropathic pain, chronic prostatitis, chronic pelvic pain syndrome, and fibromyalgia. We conclude that the role of the inflammasome in pain-associated diseases is likely to be inflammasome subtype and disease specific. The currently available evidence suggests that disease-specific targeting of the assembly and activity of the inflammasome complex may be a novel therapeutic opportunity for the treatment of refractory pain in many settings.

来源:Br J Anaesth,查看原文。版权归原作者所有。

引用

  1. Zhang H, Li F, Li WW, et al. The inflammasome as a target for pain therapy. Br J Anaesth. 2016. PMID: 27956668

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。